Akebia Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference
Akebia Therapeutics (Nasdaq: AKBA), a biopharmaceutical company focused on kidney disease treatments, has announced its participation in the upcoming H.C. Wainwright 4th Annual Kidney Virtual Conference. Chief Commercial Officer Nik Grund will engage in a Fireside Chat on Monday, July 14 at 10:00 AM EDT.
Investors and interested parties can access the presentation recording through the Investors section of Akebia's website at ir.akebia.com after the conference concludes.
Akebia Therapeutics (Nasdaq: AKBA), un'azienda biofarmaceutica specializzata in trattamenti per le malattie renali, ha annunciato la sua partecipazione alla prossima Conferenza Virtuale Annuale sul Rene H.C. Wainwright, giunta alla sua quarta edizione. Il Chief Commercial Officer Nik Grund prender脿 parte a una Fireside Chat luned矛 14 luglio alle 10:00 EDT.
Investitori e interessati potranno accedere alla registrazione della presentazione nella sezione Investors del sito web di Akebia all'indirizzo ir.akebia.com dopo la conclusione della conferenza.
Akebia Therapeutics (Nasdaq: AKBA), una compa帽铆a biofarmac茅utica enfocada en tratamientos para enfermedades renales, ha anunciado su participaci贸n en la pr贸xima Conferencia Virtual Anual sobre Ri帽贸n H.C. Wainwright, en su cuarta edici贸n. El Director Comercial Nik Grund participar谩 en una charla informal el lunes 14 de julio a las 10:00 AM EDT.
Los inversores y partes interesadas podr谩n acceder a la grabaci贸n de la presentaci贸n a trav茅s de la secci贸n de inversores del sitio web de Akebia en ir.akebia.com una vez finalizada la conferencia.
Akebia Therapeutics (雮橃姢雼�: AKBA)电� 鞁犾灔 歆堩櫂 旃橂鞐� 欷戩爯鞚� 霊� 氚旍澊鞓れ牅鞎� 須岇偓搿�, 雼り皜鞓さ鐢 H.C. Wainwright 鞝�4須� 鞐半 鞁犾灔 臧�靸� 旎嵓霟办姢鞐� 彀戈皜頃� 瓴冹瀯鞚� 氚滍憸頄堨姷雼堧嫟. 斓滉碃 靸侅梾 毂呾瀯鞛� Nik Grund电� 7鞗� 14鞚� 鞗旍殧鞚� 鞓れ爠 10鞁�(EDT)鞐� Fireside Chat鞐� 彀胳棳頃� 鞓堨爼鞛呺媹雼�.
韴瀽鞛� 氚� 甏�鞁� 鞛埖鐢 攵勲摛鞚� 旎嵓霟办姢 膦呺 頉� Akebia 鞗轨偓鞚错姼鞚� 韴瀽鞛� 靹轨厴 ir.akebia.com鞐愳劀 氚滍憸 雲鬼檾 鞓侅儊鞚� 頇曥澑頃� 靾� 鞛堨姷雼堧嫟.
Akebia Therapeutics (Nasdaq : AKBA), une soci茅t茅 biopharmaceutique sp茅cialis茅e dans les traitements des maladies r茅nales, a annonc茅 sa participation 脿 la 4e conf茅rence virtuelle annuelle sur les reins organis茅e par H.C. Wainwright. Le directeur commercial Nik Grund participera 脿 une discussion informelle le lundi 14 juillet 脿 10h00 EDT.
Les investisseurs et parties int茅ress茅es pourront acc茅der 脿 l'enregistrement de la pr茅sentation via la section investisseurs du site web d'Akebia 脿 l'adresse ir.akebia.com apr猫s la fin de la conf茅rence.
Akebia Therapeutics (Nasdaq: AKBA), ein biopharmazeutisches Unternehmen, das sich auf Nierenerkrankungen spezialisiert, hat seine Teilnahme an der bevorstehenden 4. j盲hrlichen virtuellen Nierenkonferenz von H.C. Wainwright angek眉ndigt. Chief Commercial Officer Nik Grund wird am Montag, den 14. Juli um 10:00 Uhr EDT an einem Fireside Chat teilnehmen.
Investoren und Interessierte k枚nnen die Aufzeichnung der Pr盲sentation nach der Konferenz im Investorenbereich der Akebia-Website unter ir.akebia.com abrufen.
- None.
- None.
CAMBRIDGE, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that Nik Grund, Chief Commercial Officer, will participate in a Fireside Chat at the H.C. Wainwright 4th Annual Kidney Virtual Conference on Monday, July 14 at 10:00 AM EDT.
A webcast of the presentation can be accessed through the 鈥淚nvestors鈥� section of Akebia鈥檚 website at following the conference.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at , which does not form a part of this release.
Akebia Therapeutics Contact
Mercedes Carrasco
FAQ
When is Akebia Therapeutics (AKBA) presenting at the H.C. Wainwright Kidney Conference?
Who will represent Akebia Therapeutics (AKBA) at the H.C. Wainwright Conference?
How can investors access Akebia Therapeutics' (AKBA) conference presentation?
What is the focus of Akebia Therapeutics (AKBA) as a company?
